Verition Fund Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Verition Fund Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,891	Closed	-$505K	–	3261
2025 Q4	$505K	Sell	4,891 -15,753	-76%	-$1.53M	﹤0.01%	2651
2025 Q3	$1.87M	Buy	20,644 +16,600	+410%	+$1.45M	0.01%	2035
2025 Q2	$356K	Sell	4,044 -1,015	-20%	-$88K	﹤0.01%	3121
2025 Q1	$461K	Buy	5,059 +1,015	+25%	+$91.4K	﹤0.01%	2635
2024 Q4	$349K	Buy	+4,044	New	+$366K	﹤0.01%	2686

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $16B AUM 37.57% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $12.6B AUM 31.26% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

Verition Fund Management's PPH Position: Q1 2026 in Review

Verition Fund Management sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2026, closing a stake of 4,891 shares — an estimated $505K sold.

Verition Fund Management first reported a position in PPH in Q4 2024 and held it in 5 quarters. The position peaked at $1.87M in Q3 2025. 148 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

Verition Fund Management reported no remaining VanEck Pharmaceutical ETF position as of Q1 2026 after selling out during the quarter.
Verition Fund Management sold 4,891 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $505K.
Verition Fund Management first reported a position in VanEck Pharmaceutical ETF in Q4 2024 and held it in 5 quarters.
Verition Fund Management's VanEck Pharmaceutical ETF position peaked at $1.87M in Q3 2025.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.